BCLI — Brainstorm Cell Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $36.53m
- $35.23m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 23 | 31.7 | 24.5 | 24.8 | 21.4 |
Operating Profit | -23 | -31.7 | -24.5 | -24.8 | -21.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -23.3 | -31.8 | -24.5 | -24.3 | -17.2 |
Net Income After Taxes | -23.3 | -31.8 | -24.5 | -24.3 | -17.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -23.3 | -31.8 | -24.5 | -24.3 | -17.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -23.3 | -31.8 | -24.5 | -24.3 | -17.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.06 | -1.07 | -0.676 | -0.665 | -0.399 |